Scientific Journals and Books

2025
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

Egea-Rodriguez S, Varaljai R, Nordmann T M, Lubis R, Philip M, Rambow F, Roesch A, Flaig M, Horn S, Stoll R, Zhao F, Paschen A, Klebl B, Hickson I D, Schadendorf D, Mann M and Helfrich I. Clin Transl Med. 2025; 15 (1): e70094. doi: 10.1002/ctm2.70094

P2X7R antagonism suppresses long-lasting hyperexcitability following traumatic brain injury in mice

Alves M, de Diego-Garcia L, Vegliante G, Moreno O, Gil B, Ramos-Cabrer P, Mitra M, Fernandez Martin A, Menendez Mendez A, Wang Y, Ryzwesky Strogulsky N, Sun M, Melia C, Conte G, Plaza-Garcia S, Khalin I, Teng X, Plesnila N, Klebl B, Dinkel K, Hamacher M, Bhattarcharya A, Ceusters M, Palmer J, Loane D, Llop J, Henshall D and Engel T. Theranostics. 2025; 15 (4): 1399-1419. doi: 10.7150/thno.97254

2021
Sequence-Selective Covalent CaaX-Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling

Franz M, Morchen B, Degenhart C, Gulden D, Shkura O, Wolters D, Koch U, Klebl B, Stoll R, Helfrich I, Scherkenbeck J. ChemMedChem. 2021; 16 (16): 2504-2514. doi: 10.1002/cmdc.202100167

Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt.

Meijer F A, Saris A, Doveston R G, Oerlemans G J M, de Vries R, Somsen B A, Unger A, Klebl B, Ottmann C, Cossar P J, Brunsveld L. J Med Chem. 2021; 64 (13): 9238-9258. doi: 10.1021/acs.jmedchem.1c00475

Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs)

Wild M, Kicuntod J, Seyler L, Wangen C, Bertzbach L D, Conradie A M, Kaufer B B, Wagner S, Michel D, Eickhoff J, Tsogoeva S B, Bauerle T, Hahn F, Marschall M. Int J Mol Sci. 2021; 22 (2): doi: 10.3390/ijms22020575